Omeros CEO Gregory Demopulos Receives 1,000,000-Share Award

What Happened Gregory A. Demopulos, M.D., Chairman, CEO, President and a director of Omeros Corporation (OMER), was granted 1,000,000 derivative shares as an award on July 22, 2026. The grant is reported at a $0.00 acquisition price (derivative award), so no cash was paid at grant and the filing reports a $0 transaction value. This is an award/grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-22; Form 4 filed: 2026-07-24 (filed within the typical 2-business-day Form 4 window).
• Security type: Derivative award (grant) of 1,000,000 shares; reported price $0.00; reported value $0.
• Vesting (Footnote F1): One-third vests and becomes exercisable on August 1, 2027; the remaining shares vest in 32 equal monthly installments on the first day of each month thereafter.
• Shares owned after transaction: Not specified in the provided filing details.
• No indication of a 10b5-1 plan, tax withholding, immediate sale, or gift in the disclosed transaction.

Context This was a time-based equity award to an executive, not a market purchase or sale. Such grants are common as executive compensation and do not by themselves indicate immediate buying or selling in the market. Because the award vests over time, its ultimate value to Dr. Demopulos will depend on Omeros’s stock performance and any future exercises or sales.